A Study of the Safety and Effectiveness of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy

Overview

About this study

The purpose of this study is the evaluation of the histologically proven adenoma and carcinoma detection rate in patients undergoing a full colonoscopy with and without mucosal contrast enhancement, obtained with 200 mg of Methylene Blue MMX® tablets.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Males or females, ages between 50 and 75.
  • Outpatients scheduled for screening or surveillance colonoscopy for polyps or colorectal cancer
  • Able to comprehend the full nature and purpose of the study, including possible risks and side effects.
  • Able to co-operate with the investigator and to comply with the requirements of the entire study.
  • Signed written informed consent prior to inclusion in the study.

 

Exclusion Criteria

  • Patients at high risk of colorectal cancer e.g. ulcerative colitis
  • History of or suspected hypersensitivity to the Methylene Blue and/or the formulations' ingredients
  • History of or suspected hypersensitivity to the PEG based bowel cleansing preparation and/or the formulations' ingredients.
  • History of
    • gastrointestinal obstruction or perforation
    • toxic megacolon
    • major colonic resection
    • severe diverticulitis
    • heart failure (Class III or IV)
    • serious cardiovascular disease
    • ulcerative colitis 
    • Crohn's disease

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

David Bruining, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20157190

Mayo Clinic Footer